Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records - Joseph RM, Jack RH, Morriss R, Knaggs RD, Butler D, Hollis C, Hippisley-Cox J, Coupland C.
BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepres... (Source: SafetyLit)
Source: SafetyLit - March 7, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Mild neutropenia after suicide attempt with 900 milligrams intake of mirtazapine [letter] - Mutlu OA, Kavla Y, Demirel F.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - December 13, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Mirtazapine Does Not Reduce Agitation in Dementia Patients
In randomized, double - blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 3, 2021 Category: Psychiatry Tags: Neurology, Nursing, Pharmacy, Psychiatry, Geriatrics, Journal, Source Type: news

Common antidepressant should no longer be used to treat people with dementia
A drug used to treat agitation in people with dementia is no more effective than a placebo, and might even increase mortality, according to a new study. The research, led by the University of Plymouth and published in The Lancet, has shown that antidepressant mirtazapine offered no improvement in agitation for people with dementia - and was possibly more likely to be associated with mortality than no intervention at all. (Source: World Pharma News)
Source: World Pharma News - October 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bradyarrhythmia due to mirtazapine overdose: a case of serious adverse event in a suicidal patient - Kaya FB, Kuas C, Ozakin E, Karakilic ME, Kaya S.
There are a limited number of studies on postoverdose clinical findings of mirtazapine in the literature. Our case presented an unlikely junctional rhythm, which we have not seen in the previous studies, in a patient who had bradycardia and hypotension fol... (Source: SafetyLit)
Source: SafetyLit - March 11, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Evidence of repeated mirtazapine poisoning in children by hair analysis - Kintz P, Raul JS, Ameline A.
Mirtazapine is an antidepressant drug, used to treat depression, but also, in some specific conditions, to treat obsessive-compulsive disorder and anxiety. Although mirtazapine is not a hypnotic, it can make the subject feel drowsy. Children  under the age... (Source: SafetyLit)
Source: SafetyLit - February 11, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

High blood mirtazapine concentration in a newborn - a case of suspected postpartum infanticide - Sasao A, Yonemitsu K, Ohtsu Y, Tsutsumi H, Furukawa S, Kimura-Mishima S, Nishitani Y.
We report a sudden death of an infant due to mirtazapine poisoning. A 15-day-old newborn boy was found dead when he was sleeping beside his mother who had suffered from panic disorder for approximately 1  year. After giving birth, she complained of palpita... (Source: SafetyLit)
Source: SafetyLit - January 13, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Mirtazapine Tablets (Mirtazapine) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2020 Category: Drugs & Pharmacology Source Type: news

Driving performance and neurocognitive skills of long-term users of sedating antidepressants - van der Sluiszen NNJJM, Vermeeren A, van Dijken JH, J A E van de Loo A, Veldstra JL, de Waard D, C Verster J, A Brookhuis K, Ramaekers JG.
OBJECTIVE: To assess driving performance and neurocognitive skills of long-term users of sedating antidepressants, in comparison to healthy controls. METHODS: Thirty-eight long-term (>6 months) users of amitriptyline (n = 13) and mirtazapine (n = 25) w... (Source: SafetyLit)
Source: SafetyLit - October 3, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Aurobindo Pharma Inc recalls Mirtazapine tablets in US
The product is being recalled due to a label error on declared strength. Bottles labelled as Mirtazapine 7.5 mg may contain 15 mg tablets, as per the company's announcement posted on the website of the United States Food and Drug Administration (USFDA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 1, 2020 Category: Pharmaceuticals Source Type: news

Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Mirtazapine Tablets Lot Number 03119002A3 Due to Label Error on Declared Strength
Aurobindo Pharma USA, Inc. is voluntarily recalling lot number 03119002A3 of Mirtazapine Tablets to the consumer level. The product is being recalled due to a label error on declared strength; bottles labeled as Mirtazapine 7.5 mg may contain 15 mg tablets. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 31, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Medical News Today: What to know about mirtazapine
Mirtazapine is a tetracyclic antidepressant that is available under the brand name Remeron. In this article, we provide an overview of mirtazapine, including its uses, side effects, warnings, and interactions. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 2, 2019 Category: Consumer Health News Tags: Depression Source Type: news

New Findings on Polypharmacy in Depression New Findings on Polypharmacy in Depression
Dr Peter Yellowlees talks about mirtazapine added to SSRIs or SNRIs for treatment-resistant depression in primary care.Medscape Psychiatry (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 11, 2019 Category: Psychiatry Tags: Psychiatry Commentary Source Type: news

Remeron SolTab (Mirtazapine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 26, 2019 Category: Drugs & Pharmacology Source Type: news

mirtazapine (Remeron, Soltab)
Title: mirtazapine (Remeron, Soltab)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 12/3/2018 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - December 3, 2018 Category: Psychiatry Source Type: news